Patents Assigned to GSF-Forschungszentrum fur Umwelt und Gesundheit
-
Publication number: 20040072300Abstract: According to the invention, there is provided a vector for the expression of immunoglobulin-cytokin fusion proteins in malignant B cells at least containing operably linked to each otherType: ApplicationFiled: November 18, 2003Publication date: April 15, 2004Applicants: GSF-Forschungszentrum fur Umwelt und Gesundheit, Reinhard, Skuhra, Weise & PartnerInventor: Ralph Mocikat
-
Patent number: 6681762Abstract: A device for flow rate limitation at low differential pressures, particularly for limiting the volumetric inhalation flow during inhalation of therapeutic aerosols, consists of a housing 11 including an aspiration orifice 14, an inhalation orifice 15 and a flow passage 23 disposed therebetween. The flow passage has a flat elongate cross-section with flexible large-area walls 18, 20 having a cross-sectional area adapted to be reduced, as a function of the differential pressure prevailing between the inhalation orifice and the aspiration orifice, as well as of the flexibility of the material of the walls, to a size appropriate for a predetermined volumetric maximum inhalation flow.Type: GrantFiled: March 16, 2000Date of Patent: January 27, 2004Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerhard Scheuch, Knut Sommerer, Bernhard Müllinger, Friedel Haas, Sascha Roeder
-
Patent number: 6673573Abstract: According to the invention, there is provided a vector for the expression of immunoglobulin-cytokine fusion proteins in malignant B cells at least containing operably linked to each other (a) a region of at least 1.5 kb which is homologous to a region of the &mgr; intron or the &kgr; intron and which lacks a functional C&mgr; or C&kgr; enhancer or contains a non-functional C82 or C&kgr; enhancer; (b) at least one DNA sequence encoding a domain of an immunoglobulin or a part thereof; (c) a DNA sequence encoding a cytokine; and (d) a marker gene selectable in eukaryotic B cells and lacking a functional enhancer region wherein the expression of said marker following integration is controlled by the cellular C&mgr; or C&kgr; enhancer.Type: GrantFiled: April 21, 1998Date of Patent: January 6, 2004Assignee: GSF-Forschungszentrum fur Umwelt und GesundheitInventor: Ralph Mocikat
-
Patent number: 6646253Abstract: In a gas inlet structure for an ion source, including a capillary for the admission of a sample gas, which capillary is disposed in a guide tube for discharging a sample gas into the guide tube, the guide tube has an open end disposed in the ion source. The guide tube includes a valve for the pulsed admission of a carrier gas to the guide tube. The guide tube, the valve and the capillary are supported in a sealed support housing from which the guide tube with the capillary disposed therein projects into the ion source for supplying thereto the sample gas in a pulsed manner.Type: GrantFiled: November 17, 2000Date of Patent: November 11, 2003Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Egmont Rohwer, Ralf Zimmermann, Hans Jörg Heger, Ralf Dorfner, Ulrich Boesl, Antonius Kettrup
-
Patent number: 6606989Abstract: A device for administration of a medicated aerosol via the lungs consists of an inhalation mouthpiece 11, with an associated adjustable vaporizer 12, and of a compressed-air control valve 14 through which a pre-settable (13) volumetric flow of compressed air can be discharged to the vaporizer 12 containing the liquid medicament throughout a settable period of time. For operation of the device an electronic controller is provided on which the vaporizing period of the vaporizer and a pause interval can be set, with provisions being made for triggering the beginning of the vaporizing operation by means of a pressure sensor responsive to a suction pressure in the mouthpiece.Type: GrantFiled: April 3, 2000Date of Patent: August 19, 2003Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Peter Brand, Titus Selzer, Holger Schulz, Christa Roth, Joachim Heyder
-
Publication number: 20030105287Abstract: Multiple myeloma is treated by deletion mutants of the gp130 protein of the IL-3 receptor. These mutants inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly myeloma cells.Type: ApplicationFiled: July 12, 2002Publication date: June 5, 2003Applicant: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Michael Schaeffer, Michaela Schneiderbauer, Sascha Weidler, Michael Hallek
-
Patent number: 6551592Abstract: According to the invention, a method is provided wherein intact bispecific or trispecific antibodies which at the same time bind to the T cell receptor complex of a T cell, to tumor-associated antigens on a tumor cell, and, via the Fc portion of the bispecific antibody, to Fc receptor-positive cells are used for the induction of an anti-tumour immunity in humans and animals.Type: GrantFiled: September 3, 1997Date of Patent: April 22, 2003Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Horst Lindhofer, Hans-Jochem Kolb, Stefan Thierfelder
-
Patent number: 6544312Abstract: In a device for separating the particle size spectrum of a polydisperse aerosol comprising a housing including an inlet part, a guide part, an outlet part, a nozzle insert and a separation insert, all parts are axially symmetrical and joined by centering fits so that they are easy to manufacture and can easily be assembled and also replaced. The parts are so fitted together that they are automatically centered during assembly while providing for the properly sized aerosol and air supply and particle fraction extraction channels.Type: GrantFiled: September 17, 2001Date of Patent: April 8, 2003Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Bernhard Müllinger, Joachim Heyder
-
Publication number: 20030054005Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection and therapy of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas as well as methods for the detection and therapy of diffuse gastric carcinomas.Type: ApplicationFiled: January 14, 2002Publication date: March 20, 2003Applicant: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heinz Hofler, Karl-Friedrich Becker, Elizabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
-
Publication number: 20030035792Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: May 15, 2002Publication date: February 20, 2003Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 6521449Abstract: Compositions of matter and methods for expressing a polypeptide are provided. In one aspect, a gene construct is provided that comprises an enhancer comprising particular elements or combinations of elements from the immunoglobulin &kgr; locus, the immunoglobulin heavy chain &mgr; locus, and the immunoglobulin &lgr; locus, and a promoter and polyadenylation site linked to a nucleotide sequence encoding a polypeptide from a select group. Cells comprising the gene construct, processes for producing such cells, and processes for producing the polypeptide encoded by the gene construct from such cells are also provided.Type: GrantFiled: November 4, 1999Date of Patent: February 18, 2003Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Axel Polack, Konstanze Hörtnagel, Jürgen Wolf, Susanne Mücke
-
Patent number: 6514712Abstract: The present invention provides a monoclonal or polyclonal antibody which specifically binds the Pax9 antigen as well as methods for using the same.Type: GrantFiled: January 16, 1998Date of Patent: February 4, 2003Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heiko Peters, Rudolf Balling, Heinz Höfler, Thomas Richter
-
Patent number: 6447776Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas.Type: GrantFiled: July 23, 1997Date of Patent: September 10, 2002Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heinz Höfler, Karl-Friedrich Becker, Elisabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
-
Patent number: 6436693Abstract: The present invention relates to a method for helper virus-free packaging of gene vector DNA into the virus particles of a DNA virus as well as to eukaryotic helper cells for helper virus-free packaging of gene vector DNA into the virus particles of a DNA helper virus wherein a DNA virus having a genome ≧100 kbp is employed (FIG. 1).Type: GrantFiled: November 3, 1998Date of Patent: August 20, 2002Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Henri-Jacques Delecluse, Dagmar Pich, Wolfgang Hammerschmidt
-
Patent number: 6423972Abstract: In a method and apparatus for determining neutron spectra using at least two neutron detectors which provide integral counting rates from which the spectrum of a neutron radiation can be approximated, and which consist each of a semiconductor diode, a converter layer, an inactive layer and an active layer. The various layers of each detector are different from those of the other neutron detector and so selected that the sensitivity functions of the two neutron detectors are different. An artificial neutral network is provided which is especially trained and to which the counting rates of the detectors are supplied to be processed for obtaining the neutron spectrum.Type: GrantFiled: November 8, 1999Date of Patent: July 23, 2002Assignee: GSF - Forschungszentrum für Umwelt und Gesundheit GmbHInventors: Georg Fehrenbacher, Eric Cordes, Markus Sprunck, Wolfgang Wahl
-
Patent number: 6399748Abstract: The present invention is directed to a method of prognosticating the illness development of patients with carcinoma of the breast and/or for diagnosing carcinoma of the breast, the method comprising a qualitative determination of T1 protein and/or T1-mRNA in a sample material obtained from the patient. The invention further pertains to kits for performing the methods according to the invention.Type: GrantFiled: September 21, 1999Date of Patent: June 4, 2002Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventor: Anne Katrin Werenskiold
-
Patent number: 6390115Abstract: In a method for producing a directed gas jet wherein a guided sample gas beam is generated and an auxiliary gas beam is generated and directed and guided in the same direction as, but separated from, the sample gas beam, a pulsed carrier gas stream is generated and combined with the sample gas beam such that the sample gas beam is separated into spaced pulses which are embedded between the axially spaced pulses of the carrier gas beam and the carrier gas beam with the sample gas beam embedded therein is combined with the auxiliary gas beam such that the carrier and sample gas beam is radially enveloped by the auxiliary gas beam to from the directed gas jet of a carrier and sample gas pulses enveloped in the auxiliary gas beam.Type: GrantFiled: November 17, 2000Date of Patent: May 21, 2002Assignee: GSF-Forschungszentrum für Umwelt und GesundheitInventors: Egmont Rohwer, Ralf Zimmermann, Hans Jörg Heger, Ralph Dorfner, Ulrich Boesl, Antonius Kettrup
-
Patent number: 6322787Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.Type: GrantFiled: August 5, 1999Date of Patent: November 27, 2001Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Ralph Mocikat, Horst Lindhofer
-
Patent number: 6294167Abstract: The invention concerns medicaments containing antibodies which have at least one specificity and detect the MHCII antigen of a patient to be treated. The invention further concerns antibodies with two or more specificities which detect the MHCII antigen of a patient, and diagnostic compositions containing these antibodies.Type: GrantFiled: November 23, 1998Date of Patent: September 25, 2001Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Horst Lindhofer, Stefan Thierfelder
-
Patent number: 6261839Abstract: According to the present invention, there is provided a method for the induction of a NK cell-mediated immune response ex vivo characterized in that a physiological cell suspension containing at least tumor cells or animal or human cells infected by viruses, bacteria and/or fungi (target cells) and NK cells is treated by the following process steps in the order mentioned to increase the sensitivity of the target cells for lysis by NK cells: Heat treating the cells contained in the suspension at a temperature of 38° C. to 43° C. for a period of at least 1 hour; lowering the temperature to physiological cell temperature (about 37° C.) to give the cells contained in the suspension a recovery period of at least 1 hour; addition of a compound increasing the portion of membrane-bound Hsp7O of the target cells in a concentration which is sublethal for the cells and allowing the compound to be effective for at least 30 minutes; recovery period of at least about 1 hour at 37° C.Type: GrantFiled: March 22, 1999Date of Patent: July 17, 2001Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gabriele Multhoff, Claus Botzler